Company news
Precigen, Inc. news in 2024
Precigen, Inc.'s news releases, calls and decks from 2024, newest first.
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
December 29, 2024
Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
December 26, 2024
Precigen Reports Third Quarter 2024 Financial Results and Business Updates
November 13, 2024
Precigen to Participate in the Stifel 2024 Healthcare Conference
November 11, 2024
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
September 15, 2024
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates
August 13, 2024
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th
August 8, 2024
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
August 6, 2024
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
August 5, 2024
Precigen Announces Proposed $30 Million Public Offering of Common Stock
August 5, 2024
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
July 22, 2024
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
June 2, 2024
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
May 22, 2024
Precigen Reports First Quarter 2024 Financial Results and Business Updates
May 13, 2024
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
May 7, 2024
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
April 23, 2024
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
March 27, 2024
Precigen Reports Full Year 2023 Financial Results and Business Updates
March 18, 2024
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
March 11, 2024
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
March 4, 2024
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 5, 2024
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
January 15, 2024
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
January 7, 2024